top of page

June 2022 // Communication


Read about our success story in an article published by NCCR Transcure


In a last newsletter edition from NCCR Transcure, we can look behind the scenes of our technology transfer success story. Prof. Jürg Gertsch together with our CEO Andrea Chicca, illustrate the path that led to the conception and launch of Synendos Therapeutics, a spin-off of NCCR TransCure and University of Bern. Read the full article here:


 



 

Recent Posts

See All

January 2024 // Company & Communication

Synendos granted EMA Clinical Trial Authorisation for first-in-class Endocannabinoid System modulator, SYT-510. Synendos transitions to a clinical-stage biotech company developing innovative Endocanna

July 2023 // Communication

Synendos Therapeutics AG announces that co-founder and Scientific Advisor Board member, Professor Jürg Gertsch, presented groundbreaking new findings on an endocannabinoid transporter at the 10th Gord

bottom of page